Is Haemonetics Corp. overvalued or undervalued?

As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company appears undervalued, particularly when considering its P/E ratio of 22, which is significantly higher than the peer average of 16.35, and its EV to EBITDA ratio of 13.04 compared to the peer average of 10.38. Additionally, the PEG ratio stands at 8.36, indicating a potential mispricing relative to growth expectations.
In comparison to its peers, Haemonetics Corp. shows a stronger return on equity (ROE) of 18.58% and return on capital employed (ROCE) of 12.30%, which are favorable indicators of operational efficiency. Notably, Masimo Corp. has a much higher P/E ratio of 179.74, while Bio-Rad Laboratories, Inc. has a P/E of 16.20, reinforcing Haemonetics' relative attractiveness. Despite recent underperformance with a year-to-date return of -35.63% versus the S&P 500's 13.30%, the company's strong valuation metrics suggest it may be a compelling investment opportunity moving forward.